NASH hope­ful Gen­fit pro­motes Dean Hum to pres­i­dent; Im­mune Ther­a­peu­tics CEO pass­es ba­ton to suc­ces­sor

In 1999, while Dean Hum was an as­so­ciate pro­fes­sor at Laval Uni­ver­si­ty in Que­bec, Gen­fit reached out to him. An ex­pert in the mod­u­la­tion of tran­scrip­tion fac­tors and nu­clear re­cep­tors as­so­ci­at­ed with en­docrine and car­diometa­bol­ic dis­eases, Hum jumped aboard the com­pa­ny as CSO and has been with them ever since, cur­rent­ly serv­ing as the com­pa­ny’s COO.

He has now been ap­point­ed as pres­i­dent of GEN­FIT Corp, GEN­FIT’s sub­sidiary in the US — but will still re­tain his du­ties as COO — and will be mov­ing from the com­pa­ny’s head­quar­ters in Lille, France to Gen­fit’s US-based of­fice near Boston.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER